Search

Your search keyword '"Susen, Sophie"' showing total 12 results
Start Over Author "Susen, Sophie" Language undetermined
12 results on '"Susen, Sophie"'

1. Les lésions de l’endothélium vasculaire

Author

Dupont, Annabelle, Rosa, Mickaël, Rauch, Antoine, Susen, Sophie, Institut Européen de Génomique du Diabète - European Genomic Institute for Diabetes - FR 3508 (EGID), Institut Pasteur de Lille, and Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre National de la Recherche Scientifique (CNRS)

Subjects
[SDV]Life Sciences [q-bio], General Medicine, ComputingMilieux_MISCELLANEOUS, General Biochemistry, Genetics and Molecular Biology
Abstract

International audience; No abstract available

Published
2022

2. A Combination of Two Variants p. (Val510 =) and p. (Pro2145Thrfs * 5), Responsible for von Willebrand Disease Type 3 in a Caribbean Patient

Author

Dubois, Marie, Dubois, Marie Daniela, Pierre-Louis, Serge, Rabout, Johalène, Denis, Cécile, Christophe, Olivier, Susen, Sophie, Goudemand, Jenny, Boisseau, Pierre, Neviere, Rémi, Pierre-Louis, Olivier, Hémostase, Inflammation, Thrombose (HITH - U1176 Inserm - CHU Bicêtre), Institut National de la Santé et de la Recherche Médicale (INSERM)-AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre)-Université Paris-Saclay, Université des Antilles, EA 7525 VPMC, 97275, Schoelcher, Martinique, Vulnérabilité cardiovasculaire, pathologie métabolique et endocrinienne (VCPME), Université des Antilles (UA), Ressources and Competence Center for Constitutional Hemorrhagic Diseases [CHU Martinique] (CRC-MHC), Service d'Hématologie Cellulaire [Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de génétique médicale - Unité de génétique clinique [Nantes], Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes), and CHU de la Martinique [Fort de France]

Subjects
Von Willebrand disease type 3, lcsh:Diseases of the circulatory (Cardiovascular) system, 0303 health sciences, medicine.medical_specialty, Letter to the editor, business.industry, MEDLINE, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Gastroenterology, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, lcsh:RC666-701, 030220 oncology & carcinogenesis, Internal medicine, Medicine, business, ComputingMilieux_MISCELLANEOUS, 030304 developmental biology
Abstract

International audience; No abstract available

Published
2020

3. Von Willebrand disease type 2B with a novel mutation in the VWF gene

Author

Susen Sophie, Claudine Caron, Lydia Campos, Mohammed A. Jeraiby, and Tardy Brigitte

Subjects
Adult, congenital, hereditary, and neonatal diseases and abnormalities, medicine.medical_specialty, lcsh:Medicine, Case Report, 030204 cardiovascular system & hematology, law.invention, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Hematoma, law, hemic and lymphatic diseases, Internal medicine, von Willebrand Factor, medicine, Von Willebrand disease, Humans, Platelet, Ristocetin, Gene, business.industry, lcsh:R, General Medicine, medicine.disease, von Willebrand Diseases, Endocrinology, chemistry, Hemostasis, Mutation, cardiovascular system, Recombinant DNA, Female, business, Novel mutation, circulatory and respiratory physiology, 030215 immunology
Abstract

We report a 38-year-old woman who presented with a subdural hematoma after minor facial trauma in a stressful situation. The laboratory data showed a subnormal platelet count (166×10 9 /L), VWF:RCo activity was 45% and VWF:Ag was 53% with a VWF:RCo/VWF Ag ratio of 0.79. Hemostasis results and gene analysis revealed von Willebrand disease (VWD) type 2B with normal multimers and a novel mutation c.4136 G>T (R1379L), which appears to be a novel mutation of VWD type 2B that is mainly diagnosed with hypersensitivity to ristocetin and an hyperfixation of platelet Willebrand to a recombinant Gp1b. SIMILAR CASES PUBLISHED: None.

Published
2021

4. Optogenetic and chemogenetic insights into the neurocircuitry of depression‐like behaviour: A systematic review

Author

Tom Biselli, Johannes Steffen, Andreas Walther, Susen Sophie Lange, and Lynn Sablottny

Subjects
Depressive Disorder, Major, 0303 health sciences, Depression, General Neuroscience, Hippocampus, Chemogenetics, Optogenetics, Nucleus accumbens, Amygdala, Nucleus Accumbens, Ventral tegmental area, 03 medical and health sciences, 0302 clinical medicine, medicine.anatomical_structure, Reward, medicine, Animals, Prefrontal cortex, Psychology, Neuroscience, 030217 neurology & neurosurgery, Anterior cingulate cortex, 030304 developmental biology
Abstract

Major depressive disorder (MDD) and its treatment are challenges for global health. Optogenetics and chemogenetics are driving MDD research forward by unveiling causal relations between cell-type-specific control of neurons and depressive-like behaviour in rodents. Using a systematic search process, in this review, a set of 43 original studies applying optogenetic or chemogenetic techniques in rodent models of depression was identified. Our aim was to provide an examination of all available studies elucidating central neuronal mechanisms leading to depressive-like behaviour in rodents and thereby unveiling the most promising routes for future research. A complex interacting network of relevant structures, in which central circuitries causally related to depressive-like behaviour are implicated, has been identified. As most relevant structures emerge: medial prefrontal cortex, anterior cingulate cortex, amygdala, nucleus accumbens, ventral tegmental area, hippocampus and raphe nuclei. Further evidence, though examined by only few studies, emerges for structures like the lateral habenula, or medial dorsal thalamus. Most of the identified brain areas have previously been associated with MDD neuropathology, but now evidence can be provided for causal pathological mechanisms within a complex cortico-limbic reward circuitry. However, the studies also show conflicting results concerning the mechanisms underlying the causal involvement of specific circuitries. Comparability of studies is partly limited since even small deviations in methodological approaches lead to different outcomes. Factors influencing study outcomes were identified and need to be considered in future studies (e.g. frequency used for stimulation, time and duration of stimulation, limitations of applied animal models of MDD).

Published
2019

5. Autoantibodies neutralizing type I IFNs are present in similar to 4% of uninfected individuals over 70 years old and account for similar to 20% of COVID-19 deaths

Author

Bastard, Paul, Gervais, Adrian, Le Voyer, Tom, Rosain, Jeremie, Philippot, Quentin, Manry, Jeremy, Michailidis, Eleftherios, Hoffmann, Hans-Heinrich, Eto, Shohei, Garcia-Prat, Marina, Bizien, Lucy, Parra-Martinez, Alba, Yang, Rui, Haljasmagi, Liis, Migaud, Melanie, Sarekannu, Karita, Maslovskaja, Julia, de Prost, Nicolas, Tandjaoui-Lambiotte, Yacine, Luyt, Charles-Edouard, Amador-Borrero, Blanca, Gaudet, Alexandre, Poissy, Julien, Morel, Pascal, Richard, Pascale, Cognasse, Fabrice, Troya, Jesus, Trouillet-Assant, Sophie, Belot, Alexandre, Saker, Kahina, Garcon, Pierre, Riviere, Jacques G., Lagier, Jean-Christophe, Gentile, Stephanie, Rosen, Lindsey B., Shaw, Elana, Morio, Tomohiro, Tanaka, Junko, Dalmau, David, Tharaux, Pierre-Louis, Sene, Damien, Stepanian, Alain, Megarbane, Bruno, Triantafyllia, Vasiliki, Fekkar, Arnaud, Heath, James R., Franco, Jose Luis, Anaya, Juan-Manuel, Sole-Violan, Jordi, Imberti, Luisa, Biondi, Andrea, Bonfanti, Paolo, Castagnoli, Riccardo, Delmonte, Ottavia M., Zhang, Yu, Snow, Andrew L., Holland, Steven M., Biggs, Catherine M., Moncada-Velez, Marcela, Arias, Andres Augusto, Lorenzo, Lazaro, Boucherit, Soraya, Coulibaly, Boubacar, Anglicheau, Dany, Planas, Anna M., Haerynck, Filomeen, Duvlis, Sotirija, Nussbaum, Robert L., Ozcelik, Tayfun, Keles, Sevgi, Bousfiha, Ahmed A., El Bakkouri, Jalila, Ramirez-Santana, Carolina, Paul, Stephane, Pan-Hammarstrom, Qiang, Hammarstrom, Lennart, Dupont, Annabelle, Kurolap, Alina, Metz, Christine N., Aiuti, Alessandro, Casari, Giorgio, Lampasona, Vito, Ciceri, Fabio, Barreiros, Lucila A., Dominguez-Garrido, Elena, Vidigal, Mateus, Zatz, Mayana, van de Beek, Diederik, Sahanic, Sabina, Tancevski, Ivan, Stepanovskyy, Yurii, Boyarchuk, Oksana, Nukui, Yoko, Tsumura, Miyuki, Vidaur, Loreto, Tangye, Stuart G., Burrel, Sonia, Duffy, Darragh, Quintana-Murci, Lluis, Klocperk, Adam, Kann, Nelli Y., Shcherbina, Anna, Lau, Yu-Lung, Leung, Daniel, Coulongeat, Matthieu, Marlet, Julien, Koning, Rutger, Reyes, Luis Felipe, Chauvineau-Grenier, Angelique, Venet, Fabienne, Monneret, Guillaume, Nussenzweig, Michel C., Arrestier, Romain, Boudhabhay, Idris, Baris-Feldman, Hagit, Hagin, David, Wauters, Joost, Meyts, Isabelle, Dyer, Adam H., Kennelly, Sean P., Bourke, Nollaig M., Halwani, Rabih, Sharif-Askari, Narjes Saheb, Dorgham, Karim, Sallette, Jerome, Sedkaoui, Souad Mehlal, AlKhater, Suzan, Rigo-Bonnin, Raul, Morandeira, Francisco, Roussel, Lucie, Vinh, Donald C., Ostrowski, Sisse Rye, Condino-Neto, Antonio, Prando, Carolina, Bondarenko, Anastasiia, Spaan, Andras N., Gilardin, Laurent, Fellay, Jacques, Lyonnet, Stanislas, Bilguvar, Kaya, Lifton, Richard P., Mane, Shrikant, Anderson, Mark S., Boisson, Bertrand, Beziat, Vivien, Zhang, Shen-Ying, Andreakos, Evangelos, Hermine, Olivier, Pujol, Aurora, Peterson, Part, Mogensen, Trine H., Rowen, Lee, Mond, James, Debette, Stephanie, de Lamballerie, Xavier, Duval, Xavier, Mentre, France, Zins, Marie, Soler-Palacin, Pere, Colobran, Roger, Gorochov, Guy, Solanich, Xavier, Susen, Sophie, Martinez-Picado, Javier, Raoult, Didier, Vasse, Marc, Gregersen, Peter K., Piemonti, Lorenzo, Rodriguez-Gallego, Carlos, Notarangelo, Luigi D., Su, Helen C., Kisand, Kai, Okada, Satoshi, Puel, Anne, Jouanguy, Emmanuelle, Rice, Charles M., Tiberghien, Pierre, Zhang, Qian, Cobat, Aurelie, Abel, Laurent, Casanova, Jean-Laurent, and Gunst, Jan

Subjects
INTERFERON, alpha, Science & Technology, ANTINUCLEAR, myasthenia-gravis patients, AUTOIMMUNITY, autoimmunity, Immunology, interferon, IMMUNITY, immunity, DISTINCT FUNCTIONS, PATIENT, ALPHA, ANTIBODIES, antibodies, patient, distinct functions, Life Sciences & Biomedicine, MYASTHENIA-GRAVIS PATIENTS, antinuclear
Abstract

Circulating autoantibodies (auto-Abs) neutralizing high concentrations (10 ng/mL, in plasma diluted 1 to 10) of IFN-α and/or -ω are found in about 10% of patients with critical COVID-19 pneumonia, but not in subjects with asymptomatic infections. We detect auto-Abs neutralizing 100-fold lower, more physiological, concentrations of IFN-α and/or -ω (100 pg/mL, in 1/10 dilutions of plasma) in 13.6% of 3,595 patients with critical COVID-19, including 21% of 374 patients > 80 years, and 6.5% of 522 patients with severe COVID-19. These antibodies are also detected in 18% of the 1,124 deceased patients (aged 20 days-99 years; mean: 70 years). Moreover, another 1.3% of patients with critical COVID-19 and 0.9% of the deceased patients have auto-Abs neutralizing high concentrations of IFN-β. We also show, in a sample of 34,159 uninfected subjects from the general population, that auto-Abs neutralizing high concentrations of IFN-α and/or -ω are present in 0.18% of individuals between 18 and 69 years, 1.1% between 70 and 79 years, and 3.4% >80 years. Moreover, the proportion of subjects carrying auto-Abs neutralizing lower concentrations is greater in a subsample of 10,778 uninfected individuals: 1% of individuals 80 years. By contrast, auto-Abs neutralizing IFN-β do not become more frequent with age. Auto-Abs neutralizing type I IFNs predate SARS-CoV-2 infection and sharply increase in prevalence after the age of 70 years. They account for about 20% of both critical COVID-19 cases in the over-80s, and total fatal COVID-19 cases. ispartof: SCIENCE IMMUNOLOGY vol:6 issue:62 ispartof: location:United States status: published

Published
2021

6. Coagulation markers are independent predictors of increased oxygen requirements and thrombosis in COVID‐19: Response from Original Authors Susen, et al

Author

Susen, Sophie, Rauch, Antoine, and Lenting, Peter J.

Subjects
congenital, hereditary, and neonatal diseases and abnormalities, Neutrophil extravasation, Coronavirus disease 2019 (COVID-19), biology, Microvascular thrombosis, business.industry, Hematology, Neutrophil extracellular traps, 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, Von Willebrand factor, hemic and lymphatic diseases, Immunology, cardiovascular system, biology.protein, Medicine, Platelet, business, Receptor, Neutrophil recruitment, circulatory and respiratory physiology
Abstract

We thank Bhogal and colleagues for their positive comments on our manuscript and their perspective on VWF being a potential driver of COVID-19 microvascular thrombosis rather than a mere biomarker of endotheliopathy. It is well-known that VWF promotes neutrophil recruitment to endothelial surfaces under low-shear conditions and supports neutrophil extravasation towards inflamed tissues1 . This pro-inflammatory role of VWF involves two distinct pathways: (1) a direct interaction of neutrophil receptors (PSGL1 and s2-integrins) with VWF, and (2) an indirect interaction in which neutrophils adhere to VWF-bound platelets.

Published
2020

7. Additional file 1: of TRAnexamic acid in hemorrhagic CESarean section (TRACES) randomized placebo controlled dose-ranging pharmacobiological ancillary trial: study protocol for a randomized controlled trial

Author

Anne-Sophie Ducloy-Bouthors, Jeanpierre, Emmanuelle, Imen Saidi, Anne-Sophie Baptiste, Simon, Elodie, Lannoy, Damien, Duhamel, Alain, Allorge, Delphine, Susen, Sophie, and Hennart, Benjamin

Abstract

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*. (DOC 131 kb)

Published
2018
Full Text
View/download PDF

8. Additional file 2: of TRAnexamic acid in hemorrhagic CESarean section (TRACES) randomized placebo controlled dose-ranging pharmacobiological ancillary trial: study protocol for a randomized controlled trial

Author

Anne-Sophie Ducloy-Bouthors, Jeanpierre, Emmanuelle, Imen Saidi, Anne-Sophie Baptiste, Simon, Elodie, Lannoy, Damien, Duhamel, Alain, Allorge, Delphine, Susen, Sophie, and Hennart, Benjamin

Abstract

Schedule of enrolment, interventions and assessments. (DOC 44 kb)

Published
2018
Full Text
View/download PDF

9. Additional file 1: of Therapeutic and pharmaco-biological, dose-ranging multicentre trial to determine the optimal dose of TRAnexamic acid to reduce blood loss in haemorrhagic CESarean delivery (TRACES): study protocol for a randomised, double-blind, placebo-controlled trial

Author

Anne-Sophie Bouthors, Hennart, Benjamin, Jeanpierre, Emmanuelle, Anne-Sophie Baptiste, Imen Saidi, Simon, Elodie, Lannoy, Damien, Duhamel, Alain, Allorge, Delphine, and Susen, Sophie

Abstract

Trial publication spirit check list. (DOC 130 kb)

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results